The CALERIE Trial: Calorie Restriction Slowed a Clock
Eating a quarter less for two years nudged one aging clock, left two others alone, and settled very little about living longer.

A group of researchers took 220 healthy adults, told roughly two-thirds of them to eat a quarter less food for two years, and let the rest carry on as usual. Later, other researchers ran the participants’ stored blood through three different epigenetic aging clocks. One clock said the eat-less group was aging a little slower. The other two did not notice anything.
That is basically the result of the CALERIE trial, whose full name is the Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (someone worked hard on that acronym). Adults without obesity were randomized to 25% caloric restriction or an “ad libitum” control diet for 2 years. In a post-hoc analysis, restriction slowed DunedinPACE, a clock that estimates the speed of aging, by approximately 3%. It did not produce statistically significant changes in two other clocks, PhenoAge and GrimAge. The authors call the effect sizes small. Whether a 3% slower clock means anyone lives longer is not settled.
The published analysis compresses all of this into one sentence: “In the CALERIE randomized controlled trial, 25% caloric restriction over 2 years slowed DunedinPACE by approximately 3%, but did not produce statistically significant changes in PhenoAge or GrimAge.” It is a careful sentence. If you read it slowly, the way you would read a contract you are about to sign, it turns out to contain most of what is currently known about biological age tests, and most of what isn’t.
What the CALERIE trial actually did
Start with “randomized controlled trial.” This is the expensive clause. Most of what anyone knows about biological age comes from observing people: smokers have older-looking blood, richer people have younger-looking blood, etc. Observation cannot tell you whether the habit moved the clock or whether the kind of person who has the habit was always going to have that clock. Randomization fixes this by letting a coin decide (coins have no opinions about kale).
The coin here was weighted. Participants were assigned to restriction or control in a 2:1 ratio. Picture a dinner party where the host flips a coin for each guest, except the coin is rigged so two out of every three guests get a plate one quarter smaller, and nobody gets to swap. The guests were healthy, nonobese men and premenopausal women aged 21 to 50, with BMIs between 22.0 and 27.9. These were not people with a weight problem to solve. They were ordinary-sized people asked to become slightly smaller ordinary-sized people.
The trial is registered on ClinicalTrials.gov as NCT00427193, which matters only in the sense that it existed, on paper, before anyone looked at a methylation clock. That is the other half of why randomized trials are worth their trouble.
What “25% caloric restriction over 2 years” covers
“25%” is what people were assigned. It is not necessarily what everyone did. A separate analysis of the same trial, looking at telomeres, measured something it calls caloric restriction “dose” and found it varied enough to be worth analyzing, which is a polite way of saying that people asked to eat 25% less ate various amounts less.
“Over 2 years” is the understated clause. Two years of eating three-quarters of what you would otherwise eat is, in the technical sense, a commitment. It is several hundred breakfasts (plus the lunches, which the sentence also skips). The sentence spends four words on it.
And then the blood went into freezers. The CALERIE Genomic Data Resource was later generated from stored samples from 218 participants (two of the original 220 are not accounted for in that count, and the facts available here do not say why). It includes genotypes and three timepoints of DNA methylation, mRNA and small RNA data, from blood, skeletal muscle and fat. The total is 2,327 samples.
It is worth sitting with 2,327 for a second. That is not a round number. Nobody planned 2,327. It is what you get when you take a couple hundred people, cut small pieces out of them at three points over two years, and keep every piece that survived the freezer. Every one of those samples is a person on a smaller plate.
Why the DunedinPACE number is the one that moved
“Slowed DunedinPACE” is a weird verb with a weird object. Most clocks estimate an age: your blood looks 47. DunedinPACE was trained differently, on longitudinal change rather than on predicting age at one moment. It is meant to estimate a rate, how fast a body is deteriorating right now, which is why the sentence says the clock “slowed” rather than that anyone got younger. The site’s article on DunedinPACE covers how it is built.
This matters for which clock you would expect to move in a two-year trial. The Moffitt & Caspi lab, which developed it, describes DunedinPACE as “the most sensitive epigenetic clock to intervention,” slowing most in trials and responding most consistently across studies. In trial-design terms that makes it the sexy clock: the one most likely to respond to an intervention’s advances. On the other hand, a clock that reacts to everything is also a clock you have to be careful about falling for.
There is also a family history. DunedinPoAm, the earlier version of the same idea, was validated partly in the CALERIE trial. That is not a scandal, and it does not obviously undermine the later result, but it means the clock and the trial are not strangers. How much that should matter is not settled by anything here.
“By approximately 3%” is the number everyone will remember. The same analysis gives it a translation: a 3% slower DunedinPACE “is associated with approximately 15% lower risk of death in an independent study of older adults, suggesting the CALERIE effect is clinically meaningful.” Read that literally too. Associated, not caused. Older adults, not 21-to-50-year-olds. Independent study, meaning different people. It is a bridge built from one population to another, and the bridge has not been walked across.
What “did not produce statistically significant changes” means for PhenoAge and GrimAge
Then comes “but.” PhenoAge and GrimAge are not obscure clocks. GrimAge was trained on death, which is about as serious as training gets. In this trial, restriction did not produce statistically significant changes in either.
“Not statistically significant” does not mean “did not change.” It means whatever change happened was not distinguishable from noise with this many people. Maybe they moved a bit. Maybe they did not. The sentence declines to say, which is correct.
Here is where the post-hoc part matters. The trial was designed to study eating less; the clocks came afterward, applied to stored blood. You can imagine the conversation (this is invented): “Okay, the trial is done, the primary outcomes are published, and we have freezers full of blood. Which clocks do we run?” “All the good ones, I suppose.” That is a perfectly reasonable thing to do. It also means the result is a finding to be tested, not a test that was passed.
Now push it further, purely as an invented exercise. Suppose a future trial runs 400 clocks on its freezer blood. Statistics alone will make some of them move. Each moving clock gets its own abstract, its own press release, its own consumer kit. Clock 312 reports the control group got younger. Clock 377 says everyone is aging faster except on Tuesdays. CALERIE ran three clocks and reported all three, including the two that stayed put, which is roughly the opposite of this.
The telomere analysis of the same trial is a useful reminder of how messy one intervention can look through different instruments. By intent-to-treat, there was no significant difference in telomere attrition in the first year. In a dose analysis, more restriction went with more attrition in a methylation-based telomere estimate during the weight-loss year, and with less absolute telomere attrition during the second, weight-maintenance year. So: worse, then better, depending on the year and the ruler. It’s fine. Bodies losing weight and bodies holding weight are doing different things.
What the CALERIE result does and doesn’t prove
It shows that a randomized, real-world intervention moved one well-regarded aging clock by a small, measurable amount over two years. That is not nothing. Most claims in this field never get a randomized trial at all.
What it does not show is that the clock movement stands in for anything a person would feel, such as living longer or getting sick later. That is the surrogate endpoint problem, and a 2026 systematic review of geroscience intervention trials looked at it directly. It found no trial-level validation of epigenetic clocks as surrogate endpoints, no intervention-clock-outcome combination that met the criteria for meta-analysis, and certainty of evidence “rated very low across all assessed evidence bodies.” The clocks flirt with outcomes. They have not yet been shown to commit.
Anyway, the sentence says exactly what happened. Eating less for two years changed a number in some blood. That is a real result, and it is the whole result.
Sources
- EFFECT OF LONG-TERM CALORIC RESTRICTION ON THE PACE OF BIOLOGICAL AGING IN HEALTHY ADULTS FROM THE CALERIE TRIAL
- Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial
- Effect of long-term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis
- DunedinPACE | Moffitt & Caspi: Genes, Environment, Health, Behavior
- Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm | eLife
- The CALERIE Genomic Data Resource
- Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review
Bio Clock Test explains published research. It is not medical advice and it does not diagnose anything. We never recommend a test, a supplement or a treatment. Talk to a clinician about your health.